PARAGON 28 INC (FNA)

US69913P1057 - Common Stock

10.02  -0.01 (-0.1%)

Fundamental Rating

3

Taking everything into account, FNA scores 3 out of 10 in our fundamental rating. FNA was compared to 187 industry peers in the Health Care Equipment & Supplies industry. While FNA seems to be doing ok healthwise, there are quite some concerns on its profitability. FNA is quite expensive at the moment. It does show a decent growth rate.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year FNA has reported negative net income.
In the past year FNA has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: FNA reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: FNA reported negative operating cash flow in multiple years.

1.2 Ratios

Looking at the Return On Assets, with a value of -20.89%, FNA is in line with its industry, outperforming 52.41% of the companies in the same industry.
FNA has a Return On Equity (-45.24%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -20.89%
ROE -45.24%
ROIC N/A
ROA(3y)-15.46%
ROA(5y)-7.89%
ROE(3y)-27.27%
ROE(5y)-13.33%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

FNA's Gross Margin of 75.22% is amongst the best of the industry. FNA outperforms 86.63% of its industry peers.
In the last couple of years the Gross Margin of FNA has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for FNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 75.22%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.05%
GM growth 5YN/A

More info and screens

4

2. Health

2.1 Basic Checks

FNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for FNA has been increased compared to 1 year ago.
Compared to 1 year ago, FNA has a worse debt to assets ratio.

2.2 Solvency

FNA has an Altman-Z score of 3.14. This indicates that FNA is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.14, FNA is in the better half of the industry, outperforming 68.45% of the companies in the same industry.
FNA has a Debt/Equity ratio of 0.79. This is a neutral value indicating FNA is somewhat dependend on debt financing.
FNA has a Debt to Equity ratio of 0.79. This is in the lower half of the industry: FNA underperforms 73.80% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Altman-Z 3.14
ROIC/WACCN/A
WACC8.76%

2.3 Liquidity

FNA has a Current Ratio of 3.50. This indicates that FNA is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 3.50, FNA is doing good in the industry, outperforming 63.10% of the companies in the same industry.
A Quick Ratio of 1.60 indicates that FNA should not have too much problems paying its short term obligations.
FNA has a Quick ratio (1.60) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.5
Quick Ratio 1.6

More info and screens

5

3. Growth

3.1 Past

The earnings per share for FNA have decreased strongly by -48.98% in the last year.
FNA shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.16%.
The Revenue has been growing by 24.92% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-48.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
Revenue 1Y (TTM)18.16%
Revenue growth 3Y24.92%
Revenue growth 5YN/A
Sales Q2Q%18.1%

3.2 Future

Based on estimates for the next years, FNA will show a small growth in Earnings Per Share. The EPS will grow by 6.10% on average per year.
FNA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.51% yearly.
EPS Next Y-15.44%
EPS Next 2Y7.67%
EPS Next 3Y12.39%
EPS Next 5Y6.1%
Revenue Next Year17.44%
Revenue Next 2Y16.14%
Revenue Next 3Y15.54%
Revenue Next 5Y18.51%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FNA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FNA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as FNA's earnings are expected to grow with 12.39% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.67%
EPS Next 3Y12.39%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FNA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PARAGON 28 INC

NYSE:FNA (12/23/2024, 11:23:38 AM)

10.02

-0.01 (-0.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners59.86%
Inst Owner Change7.45%
Ins Owners15.07%
Ins Owner Change1.97%
Market Cap838.87M
Analysts85.45
Price Target14.62 (45.91%)
Short Float %7.2%
Short Ratio5.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2.77%
Min EPS beat(2)0.01%
Max EPS beat(2)5.52%
EPS beat(4)2
Avg EPS beat(4)-47.2%
Min EPS beat(4)-150.24%
Max EPS beat(4)5.52%
EPS beat(8)3
Avg EPS beat(8)-33.28%
EPS beat(12)4
Avg EPS beat(12)-38.7%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)1.22%
Min Revenue beat(2)0.57%
Max Revenue beat(2)1.87%
Revenue beat(4)3
Avg Revenue beat(4)0.75%
Min Revenue beat(4)-0.83%
Max Revenue beat(4)1.87%
Revenue beat(8)7
Avg Revenue beat(8)1.01%
Revenue beat(12)11
Avg Revenue beat(12)2.92%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.46%
PT rev (3m)2.38%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-40.69%
EPS NY rev (1m)1.29%
EPS NY rev (3m)-183.26%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.85%
Revenue NY rev (1m)0.94%
Revenue NY rev (3m)-2.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.42
P/FCF N/A
P/OCF N/A
P/B 6.02
P/tB 9.02
EV/EBITDA N/A
EPS(TTM)-0.73
EYN/A
EPS(NY)-0.48
Fwd EYN/A
FCF(TTM)-0.71
FCFYN/A
OCF(TTM)-0.48
OCFYN/A
SpS2.93
BVpS1.67
TBVpS1.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.89%
ROE -45.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 75.22%
FCFM N/A
ROA(3y)-15.46%
ROA(5y)-7.89%
ROE(3y)-27.27%
ROE(5y)-13.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.05%
GM growth 5YN/A
F-Score4
Asset Turnover0.81
Health
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 103.73%
Cap/Sales 7.84%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.5
Quick Ratio 1.6
Altman-Z 3.14
F-Score4
WACC8.76%
ROIC/WACCN/A
Cap/Depr(3y)243.93%
Cap/Depr(5y)266.2%
Cap/Sales(3y)17.05%
Cap/Sales(5y)15.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-48.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
EPS Next Y-15.44%
EPS Next 2Y7.67%
EPS Next 3Y12.39%
EPS Next 5Y6.1%
Revenue 1Y (TTM)18.16%
Revenue growth 3Y24.92%
Revenue growth 5YN/A
Sales Q2Q%18.1%
Revenue Next Year17.44%
Revenue Next 2Y16.14%
Revenue Next 3Y15.54%
Revenue Next 5Y18.51%
EBIT growth 1Y-29.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year64.04%
EBIT Next 3Y41.61%
EBIT Next 5Y26.29%
FCF growth 1Y28.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.71%
OCF growth 3YN/A
OCF growth 5YN/A